Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma.

Authors:
Pelcovits A; Ollila TA; Olszewski AJ.

Journal:
Cancer Manag Res

Publication Year: 2023

DOI:
10.2147/CMAR.S330908

PMCID:
PMC10493109

PMID:
37700809

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Cancer Manag Res

Abbreviation: Cancer Manag Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer.
Wu X; Li S; Yang Y and 2 more (2024) - Transparency Score: 3/6
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractor…
Bai H; Wang WH; Zhou FF and 2 more (2024) - Transparency Score: 3/6
High Expression of WT1 and Low Expression of p53 in Archived Blocks of Children with Wilms Tumor in…
Ssenkumba B; Atwiine B; Mitala Y and 5 more (2024) - Transparency Score: 3/6
Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the …
Yang F; Li C; Qiu Y and 7 more (2024) - Transparency Score: 3/6
ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cance…
Wang Y; Ma C; Yang X and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure AJO is a Clinical Research Scholar of the Leukemia & Lymphoma Society, and reports consultancy role with Genmab; Blue Cross/Blue Shield of Rhode Island; TG Therapeutics; Schrodinger; ADC Therapeutics; BeiGene, and research funding from Genetech/Roche; Adaptive Biotechnologies; Precision Biosciences; Genmab; Kymera Therapeutics. TAO reports research funding from ONO Pharmaceuticals. AP reports no relevant conflicts of interest in this work."

Evidence found in paper:

"Disclosure: AJO is a Clinical Research Scholar of the Leukemia & Lymphoma Society, and reports consultancy role with Genmab; Blue Cross/Blue Shield of Rhode Island; TG Therapeutics; Schrodinger; ADC Therapeutics; BeiGene, and research funding from Genetech/Roche; Adaptive Biotechnologies; Precision Biosciences; Genmab; Kymera Therapeutics. TAO reports research funding from ONO Pharmaceuticals. AP reports no relevant conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025